Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (KVUE) delivers essential consumer health solutions through trusted brands like Tylenol and Neutrogena. This page serves as a comprehensive repository for official updates and analysis-driven news about the company’s operations in pain management, skincare, oral care, and women’s health.
Investors and professionals will find timely updates on earnings reports, regulatory developments, and strategic partnerships. All content is curated to provide actionable insights while maintaining strict neutrality regarding investment decisions.
The news collection covers key business areas including product innovations backed by R&D expertise, financial performance across global markets, and leadership announcements shaping corporate strategy. Content is verified against primary sources to ensure accuracy.
Bookmark this page to stay informed about Kenvue’s evolving position in the consumer health sector. Regular updates provide clarity on how the company addresses market challenges through its science-first approach and brand portfolio management.
Kimberly-Clark (NASDAQ: KMB) agreed to acquire Kenvue (NYSE: KVUE) in a cash-and-stock transaction valuing Kenvue at an enterprise value of approximately $48.7 billion (based on KMB close on Oct 31, 2025). The deal offers Kenvue shareholders $3.50 cash plus 0.14625 KMB shares (total $21.01 per KVUE share) and is expected to close in H2 2026, subject to approvals.
The combined company is projected to generate ~$32 billion revenue and ~$7 billion adjusted EBITDA in 2025, with anticipated run-rate synergies of $2.1 billion and $2.5 billion of one-time costs to capture them. Post-close ownership: ~54% KMB / 46% KVUE.
Kenvue (NYSE: KVUE) declared a quarterly cash dividend of $0.2075 per share. The dividend is payable on November 26, 2025 to shareholders of record as of the close of business on November 12, 2025. The announcement provides a dated cash return to shareholders and specifies payment and record dates.
Contact details for investor and media relations were provided.
Kenvue (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025.
The company will host a conference call and live webcast at 8:30 a.m. ET; U.S. dial-in 877-407-8835, international dial-in +1 201-689-8779. A replay will be available after the live event at investors.kenvue.com.
Contact details provided for investor and media relations. Kenvue is described as a global consumer health company with brands including Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol.
Albert Invent announced a strategic, multi-year partnership with Kenvue (NYSE: KVUE) to accelerate end-to-end R&D across Kenvue's global consumer health brands. The collaboration began in Q1 2025 and focuses on integrating Albert Invent's AI platform to digitalize workflows, unify data management, and automate hundreds of R&D processes.
Albert Invent's proprietary engine is trained on over 15 million molecular structures and is used by thousands of researchers in 30+ countries. The partnership aims to speed product development, improve quality control, and streamline regulatory compliance across Kenvue's brands.
Kenvue (NYSE: KVUE) reported challenging Q2 2025 results with declining performance across key metrics. Net sales decreased 4.0% year-over-year, with organic sales declining 4.2%. The company reported diluted EPS of $0.22 and adjusted diluted EPS of $0.29, down from $0.32 in the prior year.
Under new leadership, including Interim CEO Kirk Perry and CFO Amit Banati, Kenvue revised its FY2025 outlook downward, now expecting low-single-digit declines in net and organic sales, with adjusted diluted EPS projected at $1.00-$1.05. The company is advancing a comprehensive strategic alternatives review while implementing measures to accelerate profitable growth.
The performance decline was attributed to unfavorable value realization of 0.9%, volume decline of 3.3%, weak seasonal performance in North America, and trade inventory fluctuations. The company's gross profit margin contracted to 58.9% from 59.1% year-over-year.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, has announced a dividend increase. The company's Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, representing a 1.2% increase from the previous quarter.
The dividend will be payable on August 27, 2025, to shareholders of record as of August 13, 2025. Kenvue's portfolio includes well-known brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, will release its Q2 2025 financial results before market open on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results.
Investors can access the conference call by dialing 877-407-8835 (U.S.) or +1 201-689-8779 (international). A live webcast will be available at investors.kenvue.com, with a replay accessible after the event.
Kenvue (NYSE:KVUE), the world's largest pure-play consumer health company, announced significant leadership changes and strategic initiatives. The company has appointed Kirk Perry as Interim CEO, replacing Thibaut Mongon, effective immediately. Perry brings over 30 years of consumer products and technology experience.
The Board has initiated a comprehensive strategic review to unlock shareholder value, considering portfolio optimization and operational improvements. Additionally, Kenvue released preliminary Q2 2025 results showing a 4.0% decline in net sales and organic sales decrease of 4.2%, with adjusted diluted EPS expected between $0.28 and $0.29.
The company will provide updated full-year 2025 guidance during its complete Q2 earnings release on August 7, 2025.FAQ
What is the current stock price of Kenvue (KVUE)?
What is the market cap of Kenvue (KVUE)?
